Company Pluristem Therapeutics Inc. Nasdaq
Equities
US72940R1023
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Placenta-Based Cell Therapy
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +22.65% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Israel
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +22.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01/06/01 |
Director of Finance/CFO | 40 | 01/13/01 | |
Zami Aberman
CHM | Chairman | 70 | 26/05/26 |
Artur Machlenkin
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Nitsan Halevy
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Lior Raviv
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/01 |
Orly Amiran
PRN | Corporate Officer/Principal | - | - |
Nimrod Bar Zvi
PRN | Corporate Officer/Principal | - | - |
Efrat Kaduri
PRN | Corporate Officer/Principal | - | 01/14/01 |
Human Resources Officer | 62 | 01/07/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 15/21/15 | |
Lorne Abony
BRD | Director/Board Member | 55 | 11/23/11 |
Zami Aberman
CHM | Chairman | 70 | 26/05/26 |
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01/06/01 |
Director/Board Member | 54 | 06/21/06 | |
Director/Board Member | 61 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,388,792 | 4,101,934 ( 76.12 %) | 0 | 76.12 % |
Company contact information
Pluri, Inc.
MATAM Advanced Technology Park Building No. 5
3508409, Haifa
+972 74 710 8600
http://www.pluri-biotech.comSector
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |